API
CRL icon

Advisor Partners II’s Charles River Laboratories CRL Stock Holding History

Advisor Partners II’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$469K Buy
2,393
+63
+3% +$12.9K 0.02% 749
2023
Q2 		$490K Buy
2,330
+38
+2% +$7.56K 0.02% 616
2023
Q1 		$463K Buy
2,292
+164
+8% +$37.2K 0.03% 578
2022
Q4 		$464K Buy
2,128
+277
+15% +$60.5K 0.03% 543
2022
Q3 		$364K Buy
+1,851
New +$400K 0.03% 555

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Advisor Partners II's CRL Position: Q3 2023 in Review

Advisor Partners II increased its Charles River Laboratories (CRL) stake by 2.7% in Q3 2023, buying an estimated $12.9K and bringing the position to 2,393 shares worth $469K. The position accounts for 0.02% of the portfolio, ranked #749.

Advisor Partners II first reported a position in CRL in Q3 2022 and has held it in 5 quarters since. The position peaked at $490K in Q2 2023. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Advisor Partners II held 2,393 shares of Charles River Laboratories worth $469K as of Q3 2023.
  • Advisor Partners II bought 63 Charles River Laboratories shares in Q3 2023, an estimated $12.9K.
  • Charles River Laboratories made up 0.02% of Advisor Partners II's portfolio in Q3 2023, its #749 holding.
  • Advisor Partners II first reported a position in Charles River Laboratories in Q3 2022 and has held it in 5 quarters since.
  • Advisor Partners II's Charles River Laboratories position peaked at $490K in Q2 2023.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.